Ovarian

Cancer Docs Say 'Superblood' May Work Against Deadly Malignancies

(NBCNews.com) Apr 2, 2018 - New therapy seen as possible treatment for pancreatic cancer and triple-negative breast cancer, among others.

read article

First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer

(Morningstar) Apr 5, 2018 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today that the first patient was treated in a Phase 3 clinical trial of OTL38 in the detection of ovarian cancer.

read article

J&J Must Pay Millions Over Banker's Baby Powder Cancer Claim

(Bloomberg) Apr 5, 2018 - Johnson & Johnson and a talc mining company must pay at least $37 million to an investment banker who blamed the companies’ products for causing him to develop a deadly cancer linked to asbestos.

read article

Bayer to Showcase Data from Diverse Oncology Pipeline at AACR 2018

(Business Insider) Apr 5, 2018 - Bayer will present research from its growing oncology portfolio at the American Association for Cancer Research (AACR) 2018 Annual Meeting, taking place April 14-18 in Chicago.

read article

Penn Cancer Researchers Receive $2.7 Million from V Foundation to Better Understand PARP Inhibitors and Treat BRCA Cancers

(Penn Medicine) March 29, 2018 - Funded projects will work to better understand and treat cancers in patients with inherited mutations of the BRCA1 and BRCA2 genes, which produce tumor-suppressor proteins.

read press release

Targeted Combo Active in Advanced Ovarian Cancer

(MedPage Today) Mar 28, 2018 - The combination of a PARP inhibitor and a PD-1/PD-L1 inhibitor proved active in different populations of recurrent ovarian cancer, according to results of two preliminary clinical studies reported here at the Society of Gynecologic Oncology meeting.

read article (free registration required)

Early Research Portends Advances In Ovarian Cancer Understanding And Treatment

(SGO 2018) Mar 25, 2018 - Preliminary research presented today during the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer bodes well for advances in understanding and treatment of ovarian cancer.

read press release

Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer

(The Wistar Institute) Mar 27, 2018 - Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors, already approved by the FDA for the treatment of diseases such as leukemia, as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.

read press release

Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018

(Morningstar) Mar 29, 2018 - Fate Therapeutics, Inc. announced today initial clinical data from the ongoing APOLLO Phase 1 study of FATE-NK100 as a monotherapy following outpatient chemotherapy for the treatment of women with ovarian cancer resistant to, or recurrent on, platinum-based treatment.

read article

Rubraca® (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

(Business Insider) Apr 6, 2018 - Clovis Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca® (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

read article

Clovis Closes In On Rival PARP Drugs With Latest Approval

(BioPharma Dive) Apr 6, 2018 - Clovis Oncology Inc. has notched a label expansion for its only marketed product, Rubraca, lifting the company's stock about 5% in Friday afternoon trading.

read article

Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance

(Streetinsider) Apr 16, 2018 - Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it has received special 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its Tissue of Origin test (TOO®) following modifications made to test reagents and software.

read article

Penn Study Finds Relationship between PTEN Loss, Potential for Immune Response in BRCA 1/2-Deficient Ovarian Cancer

(Penn Medicine) Apr 13, 2018 - A new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1-2 deficient ovarian cancer is likely to respond to checkpoint inhibitor therapy.

read press release

TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®

(NASDAQ) Apr 24, 2018 - TESARO, Inc. today announced results from the QUADRA study, which was designed to assess clinical benefit of ZEJULA® treatment in heavily pre-treated patients with ovarian cancer. Results successfully achieved the pre-specified primary endpoint and demonstrated ZEJULA monotherapy activity in a biomarker selected patient population.

read article

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

(Cyclacel) Apr 16, 2018 - Cyclacel Pharmaceuticals, Inc. today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced cancers.

read corporate press release

Celldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint

(Morningstar) Apr 16, 2018 - Celldex Therapeutics, Inc. today reported that the Company’s randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans (Hazard ratio = 0.95; median PFS: glembatumumab vedotin 2.9 months vs. Xeloda 2.8 months; p=0.76).

read article

FDA Approves Rucaparib For Maintenance Treatment Of Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

(FDA.gov) Apr 6, 2018 - On April 6, 2018, the Food and Drug Administration approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

read press release

Ovarian Cancer Vaccine Shows Promising Results In Human Study

(CNN) Apr 11, 2018 - Immunotherapy has gained ground against a stubborn opponent: ovarian cancer. A personalized cancer vaccine is safe and may lengthen the lives of ovarian cancer patients, a small clinical trial found.

read article

Personalized Ovarian Cancer Vaccine Shows Promise In Pilot Trial

(Penn Medicine) Apr 11, 2018 - A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.

read press release

Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer

(Immunovaccine) Apr 24, 2018 - Following positive topline results from the ongoing Phase 1b trial, study will expand to include a Phase 2 cohort.

read corporate press release
Next Page